Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

Journal of Neurology, Neurosurgery, and Psychiatry
R C DodelW H Oertel

Abstract

Active or passive immunisation can mitigate plaque pathology in murine models of Alzheimer's disease (AD). Recently, it has been shown that antibodies against beta-amyloid (Abeta) are present in human immunoglobulin preparations (IVIgG), which specifically recognise and inhibit the neurotoxic effects of Abeta. This study reports the results from a pilot study using IVIgG in patients with AD. Five patients with AD were enrolled and received monthly IVIgG over a 6 month period. Efficacy assessment included total Abeta/Abeta(1-42) measured in the CSF/serum as well as effects on cognition (ADAS-cog; CERAD) at baseline and at 6 months following IVIgG. Following IVIgG, total Abeta levels in the CSF decreased by 30.1% (17.3-43.5%) compared to baseline (p<0.05). Total Abeta increased in the serum by 233% (p<0.05). No significant change was found in Abeta(1-42) levels in the CSF/serum. Using ADAS-cog, an improvement of 3.7+/-2.9 points was detected. Scores in the MMSE were essentially unchanged (improved in four patients, stable in one patient) following IVIgG compared to baseline. Although the sample size of this pilot study is too small to draw a clear conclusion, the results of this pilot study provide evidence for a more detailed in...Continue Reading

Citations

Jan 6, 2005·Springer Seminars in Immunopathology·Sudhir PaulMarc E Weksler
Feb 24, 2010·Journal of Artificial Organs : the Official Journal of the Japanese Society for Artificial Organs·Kazunori KawaguchiSatoshi Sugiyama
Apr 21, 2010·Journal of Clinical Immunology·Brian O'NuallainAlan Solomon
Jun 11, 2008·Neuromolecular Medicine·Esther S OhStina M Fangmark Tucker
Jul 31, 2013·Neuropharmacology·R AnandAbbas Ali Mahdi
Oct 30, 2008·Molecular Psychiatry·J K FosterR N Martins
Jan 6, 2007·Nature Clinical Practice. Neurology·Ralf GoldMarinos C Dalakas
Mar 2, 2010·Nature Reviews. Drug Discovery·Adriano Aguzzi, Tracy O'Connor
Feb 9, 2010·Nature Reviews. Neurology·Cynthia A Lemere, Eliezer Masliah
Nov 6, 2009·The Journal of Biological Chemistry·Sharad P AdekarBrian O'Nuallain
Mar 1, 2012·The Journal of Biological Chemistry·Xing WeiYansheng Du
Nov 1, 2008·The Journal of Biological Chemistry·Hiroaki TaguchiSudhir Paul
Feb 7, 2009·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Jennifer S WilsonL Stephen Miller
Feb 23, 2007·Neuroreport·Audrey J GrayYasuji Matsuoka
Sep 21, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·C E Hack, P Scheltens
Sep 21, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·B Norrving
Mar 21, 2008·Annual Review of Neuroscience·David L Brody, David M Holtzman
Feb 1, 2012·International Journal of Alzheimer's Disease·Kasia LobelloRonald Black
Nov 10, 2011·Folia Phoniatrica Et Logopaedica : Official Organ of the International Association of Logopedics and Phoniatrics (IALP)·Shelly Jo Kraft, Ehud Yairi
Sep 1, 2008·Therapeutic Advances in Neurological Disorders·Martin Stangel
Feb 26, 2013·Journal of Biomedical Science·Indre DalgedieneAurelija Zvirbliene
Jan 16, 2013·Journal of Neuroinflammation·Maike GoldJan-Philipp Bach
Jun 6, 2013·Journal of Neuroinflammation·David A Loeffler
Feb 1, 2005·Immunity & Ageing : I & a·Marc E Weksler
Jun 7, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Tiffany L SudduthDonna M Wilcock
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·J Steven JacobsenMenelas N Pangalos
Nov 26, 2010·Immunotherapy·Francesco PanzaVincenzo Solfrizzi
Feb 17, 2011·Immunotherapy·Salim Shah, Howard J Federoff
May 27, 2010·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Dragan M PavlovićSanja Totić
Apr 17, 2012·International Journal of Alzheimer's Disease·Christiane Reitz
May 2, 2014·Journal of Clinical Immunology·E M Knight, S Gandy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.